Pharmacologic modification of transperitoneal movement of water.
Investigations concerning the influence of pharmacologic agents on transperitoneal water movement are predominantly undertaken in the hope that their results can help in a restoration of net ultrafiltration (UF) volume toward normal in cases with declining UF during long-term dialysis treatment. Net UF volume represents the difference between net transcapillary UF and lymphatic absorption. The choice of a pharmacological agent for enhancing UF depends on the mechanisms responsible for net UF loss, which include: (a) early dissipation of the transperitoneal osmotic gradient; (b) decrease in the peritoneal surface area; (c) lymphomonokine overproduction; (d) enhanced lymphatic absorption; (e) high residual volumes left in the peritoneal cavity; or (f) a combination of these factors. Leakage of dialysate to the abdominal wall sometimes occurring in peritoneally dialysed patients (1), according to a definition of net UF volume, cannot be regarded as a true UF loss.